Moleculin Biotech Inc (MBRX) News

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 8-K - Current report

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...

Form DEF 14A - Other definitive proxy statements

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference PR...

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin to Present at the 37th Annual ROTH Conference PR Newswire HOUSTON, March 10, 2025 Live webcast...

Form 8-K - Current report

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity PR Newswire HOUSTON...

Form PRE 14A - Other preliminary proxy statements

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]